. Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Mult Scler 2022 Nov 30:13524585221138507. doi: 10.1177/13524585221138507.
PMID: 36448361